SBIR/STTR Research Award

INDUCTION OF SPECIFIC TRANSPLANTATION TOLERANCE

Award identifier c357777bd4cc305b1e87cb903902ff6b9a819dead9204c951452d7e03823c3d4Awarding agency Department of Health and Human Services

Award amount

$99,000

Program and phase

SBIR · Phase I

Award year

1997

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Biohybrid, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

"Creatv MicroTech proposes to develop high precision x-ray anti-scatter grids for medical imaging to improve image contrast of diseased tissue by reducing the detection of scattered x-rays produced by the imaging object. Some of the potential properties of the proposed anti-scatter grid are: (i) the grid pattern is two-dimensional, (ii) the vertical air-core opening is focused to a point x-ray source, (iii) the grid patterns can be made precisely, (iv) the grid patterns are reproducible with precision and (v) the grid ratio of grid (wall height versus grid opening size) is not restricted. In Phase I, research will concentrate on (i) evaluation of the grids for performance, (iii) evaluation of all the available approaches of making a focused grid and the associated fabrication issues. In Phase II, research will concentrate on the fabrication and testing of the focused grids." $ = TOTAL AWARD AMTS & NOT LIMITED TO PORTION OF PROJECT RELATED TO SUBJECT OF SEARCH SUBPROJECT $ = TOTAL AWARD AMOUNT DIVIDED BY NUMBER OF SUBPROJECTS SOURCE: CRISP FORMAT F FY 97 LAST UPDATE 04-07-98 1QUERY 1536 ID SEARCH 06/01/98 PAGE 212 --PROJECT NUMBER......1 R43 CA76794-01 INVESTIGATOR NAME/ADDRESS FY 97 RICE, GLENN C IRG/INTRAMURAL UNIT..ZRG2 CYTOKINE NETWORKS, INC AWARD AMOUNT......... $99,343 101 ELLIOTT AVE, WEST SEATTLE, WA 98119 PERFORMING ORGANIZATION: CYTOKINE NETWORK, INC. TITLE DEVELOPMENT OF FIBROCYTES FOR ANTICANCER THERAPY ABSTRACT: Recent studies have identified a novel population of blood-borne cells, termed fibrocytes, that have a distinct cell surface phenotype (CD34+/collagen +/CD13+/CD45+), and express each of the known surface components that are required for antigen presentation, including class I and class ll MHC molecules (HLA-DP, -DQ, and -DR), the co-stimulatory molecules CD80 and CD86, and the adhesion molecules CD11a, CD54, and CD58. Human fibrocytes induce antigen presenting cell (APC) -dependent T cell proliferation and this proliferative activity is as high as that induced by purified dendritic cells. In their present form, fibrocytes are significantly easier to isolate and culture than are dendritic cells. Importantly, mouse fibrocytes pulsed in vitro with the HIV-proteins p24 or gp 120 and delivered to a site of cutaneous injury migrate to proximal lymph nodes and specifically prime naive T cells. This project will Optimize growth and culture conditions for ex vivo human fibrocyte growth, antigen display, and induction of T-cell responses measured both in vitro and in vivo. It is expected that positive data from these studies will provide the basis for validated GLP methods required for initiation of clinical trials involving autologous fibrocytes for anti-cancer and ultimately anti-HIV therapies.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.